Investigational Immunotherapy Drug Shrinks Tumors in High-risk Neuroblastoma Patients
In a study of 34 children and teenage patients, neuroblastoma tumors shrank, some dramatically, after receiving an experimental monoclonal antibody produced on the St. Jude Children’s Research Hospital campus where the study is still underway. After completing therapy, 13 patients showed no evidence of disease. “The early response is very promising, among the best that we have seen against neuroblastoma, but we still have a long way to go,” said furst author Wayne Furman, MD, a member of the St. Jude Department of Oncology. “Will this translate into more clues? We hope so, but the answer is several years away.” To read more, click here.
No upcoming events